TG Therapeutics, Inc. (TGTX)
- Previous Close
13.82 - Open
13.99 - Bid 13.95 x 300
- Ask 14.00 x 200
- Day's Range
13.85 - 14.63 - 52 Week Range
6.46 - 35.67 - Volume
3,483,645 - Avg. Volume
3,537,827 - Market Cap (intraday)
2.16B - Beta (5Y Monthly) 2.32
- PE Ratio (TTM)
155.44 - EPS (TTM)
0.09 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.43
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
www.tgtherapeutics.comRecent News: TGTX
Performance Overview: TGTX
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TGTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TGTX
Valuation Measures
Market Cap
2.16B
Enterprise Value
2.05B
Trailing P/E
155.44
Forward P/E
140.85
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.89
Price/Book (mrq)
13.46
Enterprise Value/Revenue
8.79
Enterprise Value/EBITDA
78.68
Financial Highlights
Profitability and Income Statement
Profit Margin
5.42%
Return on Assets (ttm)
4.93%
Return on Equity (ttm)
11.57%
Revenue (ttm)
233.66M
Net Income Avi to Common (ttm)
12.67M
Diluted EPS (ttm)
0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
217.51M
Total Debt/Equity (mrq)
69.25%
Levered Free Cash Flow (ttm)
-47.55M
Research Analysis: TGTX
Analyst Price Targets
Fair Value
Analyst Recommendations
Earnings
Research Reports: TGTX
Daily – Vickers Top Buyers & Sellers for 01/08/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/15/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/27/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/09/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.